Review on lipegfilgrastim
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we...
Main Authors: | Gasparic M, Leyman S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-11-01
|
Series: | International Journal of Nanomedicine |
Online Access: | https://www.dovepress.com/review-on-lipegfilgrastim-peer-reviewed-article-IJN |
Similar Items
-
Lipegfilgrastim in patients with chemotherapy-induced neutropenia
by: G. D. Petrova, et al.
Published: (2015-12-01) -
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
by: Hoggatt J, et al.
Published: (2015-04-01) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
by: Guariglia R, et al.
Published: (2016-01-01) -
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
by: Hoggatt J, et al.
Published: (2015-08-01) -
Immunogenicity Assessment of Lipegfilgrastim in Patients with Breast Cancer Receiving Chemotherapy
by: Linglong Zou, et al.
Published: (2016-01-01)